Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
07:28:15 EDT Mon 11 May 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:TVTX - TRAVERE THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
TVTX - Q7.041.19·42.997.042.6032.14    48.60  13.8807:05:40May 0715 min RT 2¢

Recent Trades - All 4 today
Time ETExPriceChangeVolume
07:05:40Q42.00-0.601
07:05:25Q41.97-0.631
07:05:10Q41.61-0.991
07:05:06Q41.60-1.001
06:47:55Q42.55-0.0525
06:47:55Q42.55-0.0525
06:47:43Q42.55-0.0525
06:47:43Q42.55-0.0525
06:47:26Q42.58-0.021
06:47:26Q42.55-0.051

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-07 16:30U:TVTXNews ReleaseTravere Therapeutics to Participate at Upcoming Investor Conferences
2026-05-06 22:28U:TVTXNews ReleaseTravere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
2026-05-05 16:01U:TVTXNews ReleaseTravere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
2026-05-04 16:01U:TVTXNews ReleaseTravere Therapeutics Reports First Quarter 2026 Financial Results
2026-04-27 16:30U:TVTXNews ReleaseTravere Therapeutics to Report First Quarter 2026 Financial Results
2026-04-14 17:00U:TVTXNews ReleaseTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-14 07:00U:TVTXNews ReleaseLigand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI(TM) (sparsentan) in FSGS
2026-04-13 18:16U:TVTXNews ReleaseTravere Therapeutics Announces Full FDA Approval of FILSPARI(TM) (sparsentan), the First and Only Approved Medicine for FSGS
2026-02-19 16:01U:TVTXNews ReleaseTravere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-12 16:30U:TVTXNews ReleaseTravere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
2026-02-11 17:00U:TVTXNews ReleaseTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-02-04 16:30U:TVTXNews ReleaseTravere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
2026-01-13 13:24U:TVTXNews ReleaseTravere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI(TM) (sparsentan) in FSGS
2026-01-12 17:00U:TVTXNews ReleaseTravere Therapeutics Provides Corporate Update and 2026 Outlook
2026-01-05 16:30U:TVTXNews ReleaseTravere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2025-12-11 17:00U:TVTXNews ReleaseTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-10 17:00U:TVTXNews ReleaseTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-06 11:00U:TVTXNews ReleaseTravere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
2025-11-04 17:23U:TVTXNews ReleaseTravere Therapeutics to Participate at Upcoming Investor Conferences
2025-10-30 16:01U:TVTXNews ReleaseTravere Therapeutics Reports Third Quarter 2025 Financial Results